Evaluation of the ability of linezolid and tedizolid to eradicate intraosteoblastic and biofilm-embedded <i>Staphylococcus aureus</i> in the bone and joint infection setting

Abstract

Linezolid and tedizolid alone are not optimal candidates to target bacterial phenotypes associated with chronic forms of BJI. Despite weak intracellular activity, they both reduce infection-related cytotoxicity, suggesting a role in modulating intracellular expression of staphylococcal virulence factors. Although inactive against biofilm-embedded S. aureus, both-but particularly tedizolid-are able to prevent biofilm formation.